Black Rock Inc. Lineage Cell Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,559,466 shares of LCTX stock, worth $6.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,559,466
Previous 8,494,395
12.54%
Holding current value
$6.31 Million
Previous $12.6 Million
23.96%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$32.7 Million1.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$5.89 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$4.17 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$3.72 Million3.45% of portfolio
-
Geode Capital Management, LLC Boston, MA4.49MShares$2.96 Million0.0% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $112M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...